These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

518 related articles for article (PubMed ID: 26210240)

  • 21. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases.
    van den Hoven AF; Rosenbaum CE; Elias SG; de Jong HW; Koopman M; Verkooijen HM; Alavi A; van den Bosch MA; Lam MG
    J Nucl Med; 2016 Jul; 57(7):1014-9. PubMed ID: 26912436
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standardized Added Metabolic Activity Predicts Survival After Intra-arterial Resin-Based 90Y Radioembolization Therapy in Unresectable Chemorefractory Metastatic Colorectal Cancer to the Liver.
    Edalat F; Camacho JC; Kokabi N; Kendi AT; Galt JR; Kim HS
    Clin Nucl Med; 2016 Feb; 41(2):e76-81. PubMed ID: 26447380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
    Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
    J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The impact of KRAS mutations on prognosis in surgically resected colorectal cancer patients with liver and lung metastases: a retrospective analysis.
    Kim HS; Heo JS; Lee J; Lee JY; Lee MY; Lim SH; Lee WY; Kim SH; Park YA; Cho YB; Yun SH; Kim ST; Park JO; Lim HY; Choi YS; Kwon WI; Kim HC; Park YS
    BMC Cancer; 2016 Feb; 16():120. PubMed ID: 26887348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
    Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
    Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis.
    Kokabi N; Camacho JC; Xing M; El-Rayes BF; Spivey JR; Knechtle SJ; Kim HS
    Cancer; 2015 Jul; 121(13):2164-74. PubMed ID: 25847227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases.
    Martin LK; Cucci A; Wei L; Rose J; Blazer M; Schmidt C; Khabiri H; Bloomston M; Bekaii-Saab T
    Clin Colorectal Cancer; 2012 Sep; 11(3):195-9. PubMed ID: 22277350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer.
    Margonis GA; Buettner S; Andreatos N; Kim Y; Wagner D; Sasaki K; Beer A; Schwarz C; Løes IM; Smolle M; Kamphues C; He J; Pawlik TM; Kaczirek K; Poultsides G; Lønning PE; Cameron JL; Burkhart RA; Gerger A; Aucejo FN; Kreis ME; Wolfgang CL; Weiss MJ
    JAMA Surg; 2018 Jul; 153(7):e180996. PubMed ID: 29799910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival outcomes of a salvage patient population after radioembolization of hepatic metastases with yttrium-90 microspheres.
    Evans KA; Richardson MG; Pavlakis N; Morris DL; Liauw W; Bester L
    J Vasc Interv Radiol; 2010 Oct; 21(10):1521-6. PubMed ID: 20813542
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radioembolization with Yttrium-90 microspheres (SIRT) in pancreatic cancer patients with liver metastases: efficacy, safety and prognostic factors.
    Michl M; Haug AR; Jakobs TF; Paprottka P; Hoffmann RT; Bartenstein P; Boeck S; Haas M; Laubender RP; Heinemann V
    Oncology; 2014; 86(1):24-32. PubMed ID: 24401529
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis.
    Margonis GA; Kim Y; Spolverato G; Ejaz A; Gupta R; Cosgrove D; Anders R; Karagkounis G; Choti MA; Pawlik TM
    JAMA Surg; 2015 Aug; 150(8):722-9. PubMed ID: 26038887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with
    Narsinh KH; Van Buskirk M; Kennedy AS; Suhail M; Alsaikhan N; Hoh CK; Thurston K; Minocha J; Ball DS; Cohen SJ; Cohn M; Coldwell DM; Drooz A; Ehrenwald E; Kanani S; Nutting CW; Moeslein FM; Savin MA; Schirm S; Putnam SG; Sharma NK; Wang EA; Rose SC
    Radiology; 2017 Jan; 282(1):281-288. PubMed ID: 27440733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases.
    Seidensticker R; Denecke T; Kraus P; Seidensticker M; Mohnike K; Fahlke J; Kettner E; Hildebrandt B; Dudeck O; Pech M; Amthauer H; Ricke J
    Cardiovasc Intervent Radiol; 2012 Oct; 35(5):1066-73. PubMed ID: 21800231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Not All Kirsten Rat Sarcoma Viral Oncogene Homolog Mutations Predict Poor Survival in Patients With Unresectable Colorectal Liver Metastasis.
    Lin Z; Liu Y; Cai S; Yang C; Zhou L; Li W
    Technol Cancer Res Treat; 2021; 20():15330338211039131. PubMed ID: 34669528
    [No Abstract]   [Full Text] [Related]  

  • 35. Primary Tumor Resection Offers Higher Survival Advantage in KRAS Mutant Metastatic Colorectal Cancer Patients.
    Kodaz H; Erdogan B; Hacibekiroglu I; Turkmen E; Tozkir H; Albayrak D; Uzunoglu S; Cicin I
    Hepatogastroenterology; 2015 Jun; 62(140):876-9. PubMed ID: 26902020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and genetic determinants of ovarian metastases from colorectal cancer.
    Ganesh K; Shah RH; Vakiani E; Nash GM; Skottowe HP; Yaeger R; Cercek A; Lincoln A; Tran C; Segal NH; Reidy DL; Varghese A; Epstein AS; Sonoda Y; Chi D; Guillem J; Temple L; Paty P; Hechtman J; Shia J; Weiser M; Aguilar JG; Kemeny N; Berger MF; Saltz L; Stadler ZK
    Cancer; 2017 Apr; 123(7):1134-1143. PubMed ID: 27875625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety, Efficacy, and Prognostic Factors After Radioembolization of Hepatic Metastases from Breast Cancer: A Large Single-Center Experience in 81 Patients.
    Fendler WP; Lechner H; Todica A; Paprottka KJ; Paprottka PM; Jakobs TF; Michl M; Bartenstein P; Lehner S; Haug AR
    J Nucl Med; 2016 Apr; 57(4):517-23. PubMed ID: 26742710
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
    Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
    AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
    [No Abstract]   [Full Text] [Related]  

  • 39. KRAS Status as a Predictor of Chemotherapy Activity in Patients With Metastatic Colorectal Cancer.
    Yarom N; Gresham G; Boame N; Jonker D
    Clin Colorectal Cancer; 2019 Dec; 18(4):e309-e315. PubMed ID: 31547963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Yttrium-90 radioembolization for the treatment of chemorefractory colorectal liver metastases: Technical results, clinical outcome and factors potentially influencing survival.
    Maleux G; Deroose C; Laenen A; Verslype C; Heye S; Haustermans K; De Hertogh G; Sagaert X; Topal B; Aerts R; Prenen H; Vanbeckevoort D; Vandecaveye V; Van Cutsem E
    Acta Oncol; 2016; 55(4):486-95. PubMed ID: 26625262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.